Zimpfer A, Went P, Tzankov A, Pehrs A-C, Lugli A, Maurer R, Terracciano L, Pileri S, Dirnhofer S
Institute of Pathology, University of Basel, Basel, Switzerland.
Histopathology. 2004 Oct;45(4):398-404. doi: 10.1111/j.1365-2559.2004.01968.x.
Imatinib mesylate specifically inhibits KIT tyrosine kinase activity, and has been proven to be effective in the treatment of gastrointestinal stromal tumours. Because other KIT-expressing malignancies might benefit from Imatinib therapy, we evaluated the distribution and expression of KIT in 1166 cases of malignant lymphoma.
Tissue microarrays (TMAs) containing 824 non-Hodgkin's lymphoma (NHL) and 342 Hodgkin's lymphoma (HL) cases were immunohistochemically analysed for the expression of the KIT protein. Two KIT-positive NHLs were sequenced using polymerase chain reaction analysis. One T-cell lymphoma and one follicular lymphoma of the 747 NHL cases (0.3%) were positive for KIT. All HLs were Kit-negative. None of the KIT-positive cases showed a kit gene mutation.
KIT expression is a very rare event in NHL and virtually absent in HL. In the few positive cases, the aberrant expression is not caused by a mutation in the 'hot-spots' of the kit gene, indicating that treatment of these tumours with Imatinib may be ineffective.
甲磺酸伊马替尼可特异性抑制KIT酪氨酸激酶活性，且已被证明在治疗胃肠道间质瘤方面有效。由于其他表达KIT的恶性肿瘤可能从伊马替尼治疗中获益，我们评估了1166例恶性淋巴瘤中KIT的分布及表达情况。
采用免疫组织化学方法分析了包含824例非霍奇金淋巴瘤（NHL）和342例霍奇金淋巴瘤（HL）病例的组织微阵列（TMA）中KIT蛋白的表达。对2例KIT阳性的NHL进行聚合酶链反应分析测序。747例NHL病例中有1例T细胞淋巴瘤和1例滤泡性淋巴瘤KIT呈阳性（0.3%）。所有HL病例KIT均为阴性。KIT阳性病例均未显示KIT基因突变。
KIT表达在NHL中是非常罕见的事件，在HL中几乎不存在。在少数阳性病例中，异常表达并非由KIT基因“热点”区域的突变引起，这表明用伊马替尼治疗这些肿瘤可能无效。
